| Filed |
Name |
|
Company |
Pur. £ |
Cur. £ |
P/L % |
MPV* |
|
Feb '17
|
Lord Arbuthnot of Edrom
|
|
Neuro-bio / NMS:NBIX |
£43.24
|
£149.59
|
245.95%
|
£242,166.96
|
|
Apr '16
|
Baroness Greenfield
|
|
Neuro-bio / NMS:NBIX |
£46.13
|
£149.59
|
224.28%
|
£226,995.44
|
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Journey Medical / NCM:DERM |
£3.74
|
£7.25
|
93.85%
|
£135,695.19**
|
|
Jul '23
|
Lord Sassoon
|
|
Haleon / LSE:HLN.L |
£336.10
|
£331.83
|
-1.27%
|
£69,110.89
|
|
Mar '17
|
Lord Lloyd-Webber
|
|
Hikma Pharmaceuticals / LSE:HIK.L |
£2,026.00
|
£1,410.50
|
-30.38%
|
£48,733.96
|
|
Mar '25
|
Lord Fink
|
|
Zoetis / NYQ:ZTS |
£162.82
|
£87.31
|
-46.38%
|
£37,536.54
|
|
Apr '21
|
Baroness Deech
|
|
Zoetis / NYQ:ZTS |
£168.10
|
£87.31
|
-48.06%
|
£36,357.52
|
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Evotec / NMS:EVO |
£7.13
|
£3.41
|
-52.17%
|
£33,478.26**
|
* Minimum Potential Value based on £70,000.00 invested at time of declaration.
** Interest ceased/exited on filed date.